Adenosine for myocardial protection in acute myocardial infarction (Q41531538)

2 October 2017

1 reference

title

Adenosine for myocardial protection in acute myocardial infarction (English)

1 reference

2 October 2017

author

Christopher B. Granger

series ordinal

1

object named as

C B Granger

1 reference

2 October 2017

language of work or name

English

0 references

publication date

1 June 1997

1 reference

American Journal of Cardiology

2 October 2017

published in

1 reference

2 October 2017

volume

79

1 reference

2 October 2017

issue

12A

1 reference

2 October 2017

page(s)

44-48

1 reference

Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients

2 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900263-4

The wavefront phenomenon of ischemic cell death. 1. Myocardial infarct size vs duration of coronary occlusion in dogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900263-4

Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. GUSTO-I Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900263-4

The "no-reflow" phenomenon after temporary coronary occlusion in the dog.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900263-4

Does reperfusion injury exist in humans?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900263-4

Canine myocardial reperfusion injury. Its reduction by the combined administration of superoxide dismutase and catalase.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900263-4

Effects of calcium antagonists on infarcting myocardium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900263-4

Enhancement of salvage of reperfused myocardium by early beta-adrenergic blockade (timolol)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900263-4

Acute myocardial infarction, reperfusion injury, and intravenous magnesium therapy: basic concepts and clinical implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900263-4

Iloprost inhibits neutrophil function in vitro and in vivo and limits experimental infarct size in canine heart

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900263-4

Reduction in reperfusion-induced myocardial necrosis in dogs by RheothRx injection (poloxamer 188 N.F.), a hemorheological agent that alters neutrophil function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900263-4

Adjunctive selectin blockade successfully reduces infarct size beyond thrombolysis in the electrolytic canine coronary artery model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900263-4

Reduction of reperfusion injury in the canine preparation by intracoronary adenosine: importance of the endothelium and the no-reflow phenomenon.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900263-4

Intracoronary adenosine administered after reperfusion limits vascular injury after prolonged ischemia in the canine model.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900263-4

Intracoronary adenosine administration during reperfusion following 3 hours of ischemia: effects on infarct size, ventricular function, and regional myocardial blood flow

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900263-4

Combined adenosine and lidocaine administration limits myocardial reperfusion injury.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900263-4

Reduction of myocardial reperfusion injury by intravenous adenosine administered during the early reperfusion period.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900263-4

Myocardial reperfusion injury in the canine model after 40 minutes of ischemia: effect of intracoronary adenosine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900263-4

A pooled analysis of coronary arterial patency and left ventricular function after intravenous thrombolysis for acute myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900263-4

Systolic left ventricular function after reperfusion therapy for acute myocardial infarction. Analysis of determinants of improvement. The TAMI Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900263-4

Cardiac rupture, mortality and the timing of thrombolytic therapy: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900263-4

An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900263-4

The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900263-4

Mortality within 24 hours of thrombolysis for myocardial infarction. The importance of early reperfusion. The GUSTO Investigators, Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900263-4

Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900263-4

Combined tissue-type plasminogen activator and prostacyclin therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 4 Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900263-4

Intravenous Fluosol in the treatment of acute myocardial infarction. Results of the Thrombolysis and Angioplasty in Myocardial Infarction 9 Trial. TAMI 9 Research Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900263-4

Beta blockade during and after myocardial infarction: an overview of the randomized trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900263-4

Surrogate end points in clinical trials: are we being misled?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900263-4

Protective effects of adenosine in myocardial ischemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900263-4

Adenosine attenuates reperfusion injury following regional myocardial ischaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900263-4

Influence of ribose, adenosine, and "AICAR" on the rate of myocardial adenosine triphosphate synthesis during reperfusion after coronary artery occlusion in the dog

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900263-4

Adenosine inhibits exocytotic release of endogenous noradrenaline in rat heart: a protective mechanism in early myocardial ischemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900263-4

Adenosine: a physiological modulator of superoxide anion generation by human neutrophils.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900263-4

Adenosine: an endogenous inhibitor of neutrophil-mediated injury to endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900263-4

A comparison of adenosine-induced cardioprotection and ischemic preconditioning in dogs. Efficacy, time course, and role of KATP channels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900263-4

Infarct size-limiting effect of ischemic preconditioning is blunted by inhibition of 5'-nucleotidase activity and attenuation of adenosine release

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900263-4

Protection against infarction afforded by preconditioning is mediated by A1 adenosine receptors in rabbit heart

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900263-4

Illusion of reperfusion. Does anyone achieve optimal reperfusion during acute myocardial infarction?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900263-4

Myocardium at risk and infarct size after thrombolytic therapy for acute myocardial infarction: implications for the design of randomized trials of acute intervention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2897%2900263-4

10.1016/S0002-9149(97)00263-4

7 January 2021

Identifiers

DOI

1 reference

2 October 2017

1 reference